96 related articles for article (PubMed ID: 15828831)
1. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
Cianchetta G; Singleton RW; Zhang M; Wildgoose M; Giesing D; Fravolini A; Cruciani G; Vaz RJ
J Med Chem; 2005 Apr; 48(8):2927-35. PubMed ID: 15828831
[TBL] [Abstract][Full Text] [Related]
2. Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.
Müller H; Pajeva IK; Globisch C; Wiese M
Bioorg Med Chem; 2008 Mar; 16(5):2448-62. PubMed ID: 18083034
[TBL] [Abstract][Full Text] [Related]
3. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
4. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach.
Wang YH; Li Y; Yang SL; Yang L
J Chem Inf Model; 2005; 45(3):750-7. PubMed ID: 15921464
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 3 assay systems using a common probe substrate, calcein AM, for studying P-gp using a selected set of compounds.
Szerémy P; Pál A; Méhn D; Tóth B; Fülöp F; Krajcsi P; Herédi-Szabó K
J Biomol Screen; 2011 Jan; 16(1):112-9. PubMed ID: 21057029
[TBL] [Abstract][Full Text] [Related]
6. P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.
Acharya P; Tran TT; Polli JW; Ayrton A; Ellens H; Bentz J
Biochemistry; 2006 Dec; 45(51):15505-19. PubMed ID: 17176072
[TBL] [Abstract][Full Text] [Related]
7. Rational use of in vitro P-glycoprotein assays in drug discovery.
Polli JW; Wring SA; Humphreys JE; Huang L; Morgan JB; Webster LO; Serabjit-Singh CS
J Pharmacol Exp Ther; 2001 Nov; 299(2):620-8. PubMed ID: 11602674
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophoric fingerprint method (TOPP) for 3D-QSAR modeling: application to CYP2D6 metabolic stability.
Sciabola S; Morao I; de Groot MJ
J Chem Inf Model; 2007; 47(1):76-84. PubMed ID: 17238251
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Schwab D; Fischer H; Tabatabaei A; Poli S; Huwyler J
J Med Chem; 2003 Apr; 46(9):1716-25. PubMed ID: 12699389
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR studies on UDP-glucuronosyltransferase 2B7 substrates using the pharmacophore and VolSurf approaches.
Ako R; Dong D; Wu B
Xenobiotica; 2012 Sep; 42(9):891-900. PubMed ID: 22494439
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial QSAR modeling of P-glycoprotein substrates.
de Cerqueira Lima P; Golbraikh A; Oloff S; Xiao Y; Tropsha A
J Chem Inf Model; 2006; 46(3):1245-54. PubMed ID: 16711744
[TBL] [Abstract][Full Text] [Related]
12. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
Desai PV; Sawada GA; Watson IA; Raub TJ
Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
[TBL] [Abstract][Full Text] [Related]
13. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
14. Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm.
Huang J; Ma G; Muhammad I; Cheng Y
J Chem Inf Model; 2007; 47(4):1638-47. PubMed ID: 17608407
[TBL] [Abstract][Full Text] [Related]
15. A 3D linear solvation energy model to quantify the affinity of flavonoid derivatives toward P-glycoprotein.
Boccard J; Bajot F; Di Pietro A; Rudaz S; Boumendjel A; Nicolle E; Carrupt PA
Eur J Pharm Sci; 2009 Feb; 36(2-3):254-64. PubMed ID: 18955135
[TBL] [Abstract][Full Text] [Related]
16. Quantification and characterization of P-glycoprotein-substrate interactions.
Gatlik-Landwojtowicz E; Aänismaa P; Seelig A
Biochemistry; 2006 Mar; 45(9):3020-32. PubMed ID: 16503657
[TBL] [Abstract][Full Text] [Related]
17. Predicting MDCK cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis.
Chen LL; Yao J; Yang JB; Yang J
Acta Pharmacol Sin; 2005 Nov; 26(11):1322-33. PubMed ID: 16225754
[TBL] [Abstract][Full Text] [Related]
18. Quantitative structure activity relationship and pharmacophore studies of adenosine receptor A2B inhibitors.
Joseph TB; Suneel Kumar BV; Santhosh B; Kriti S; Pramod AB; Ravikumar M; Kishore M
Chem Biol Drug Des; 2008 Nov; 72(5):395-408. PubMed ID: 19012575
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of immune complex-mediated neutrophil oxidative metabolism: a pharmacophore model for 3-phenylcoumarin derivatives using GRIND-based 3D-QSAR and 2D-QSAR procedures.
Kabeya LM; da Silva CH; Kanashiro A; Campos JM; Azzolini AE; Polizello AC; Pupo MT; Lucisano-Valim YM
Eur J Med Chem; 2008 May; 43(5):996-1007. PubMed ID: 17804122
[TBL] [Abstract][Full Text] [Related]
20. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
